Dendritic Cell Vaccine Production Facility: From Design to Operation

by Nicolas Taquet et al.
Volume 7, Issue 1 (Spring 2008)

In order to move product development forward, the majority of biotech companies and academic institutions involved in cell-based therapies need new facilities in order to scale up production capabilities and comply with evolving regulatory requirements. Some institutions choose to use a contract manufacturing organization (CMO) to benefit from established expertise while others support their clinical development programs with their own dedicated production facility. The main challenges in establishing a dedicated pilot-scale production facility are described hereafterā€¦

Citation:
Taquet N et al. Dendritic Cell Vaccine Production Facility: From Design to Operation. BioProcess J, 2008; 7(1): 28-33. http://dx.doi.org/10.12665/J71.Taquet.